Suprema BioStation 3 sets record as facial ID demand soars

Suprema expects its BioStation 3 facial authentication device to set a new annual global sales record this year, marking the highest yearly sales figure in the Korean company's biometric portfolio and signalling wider adoption of face-based security systems.

The company said the performance reflects sustained growth in multiple geographies rather than reliance on a single large market. BioStation 3 has recorded more than 30% year-on-year sales growth in key regions, including the United Kingdom, the Americas, Japan and the Middle East.

Suprema has positioned BioStation 3 as a core access control device for sites with strict security requirements. The company reported deployments ranging from 600 units to more than 1,000 units at public institutions, financial organisations and large-scale residential complexes.

The roll-out at what the company describes as high-security locations has reinforced BioStation 3's presence in the global security market. Suprema said it expects broader adoption across a wider range of industry sectors next year.

Regional momentum

The spread of deployments across mature and emerging security markets indicates a rising comfort level with facial authentication. Markets such as the United States and the United Kingdom have historically moved more cautiously in this area due to regulatory and privacy concerns.

Suprema said BioStation 3 has gained a foothold in those markets and is now being used in major projects. It cited a combination of facial recognition performance, user experience design, and data protection measures as the main drivers of customer interest.

BioStation 3 uses artificial intelligence for facial authentication. Suprema said this delivers high accuracy and stable performance in real-world environments. The company positions the device for secure access authentication for both administrators and end users.

The device's interface and workflows are designed for everyday operating conditions. Suprema said this design approach aims to balance user convenience with the security expectations of site operators, including in environments with complex access policies.

Data protection focus

Suprema has put explicit emphasis on data protection and privacy controls for BioStation 3. The device complies with the European Union's General Data Protection Regulation. The regulation is widely regarded as one of the most stringent data protection regimes.

BioStation 3 has also passed iBeta's ISO/IEC 30107-3 Presentation Attack Detection test for facial spoofing. The evaluation tests a system's ability to identify attempts to trick biometric sensors using photos, videos or masks.

The device incorporates a range of data protection and encryption technologies. Suprema has also introduced its Template on Mobile authentication method for the system. This feature stores and manages biometric templates on users' mobile devices rather than in a central database.

The company said this approach gives individuals direct control over their personal data. It argued that this privacy model has helped build trust among customers in markets with strict regulatory frameworks and more conservative attitudes towards facial biometrics.

Suprema expects these privacy and security features to support further deployments of BioStation 3 across industries handling sensitive information and operating under tighter compliance requirements.

Industry recognition

BioStation 3 has also received recognition from security professionals. The device won the Best Product award in the Biometrics category at the 2025 Readers' Choice Awards organised by Security Buyer magazine.

Security Buyer covers global security industry trends and emerging technologies. The Readers' Choice Awards recognise products whose innovation and market potential have been validated by votes from security professionals.

Suprema said the combination of record sales and an industry award indicates growing acceptance of AI-based facial authentication in mainstream security programmes. The company views the recognition from practitioners as an endorsement of BioStation 3's performance in live environments.

Hanchul Kim, Chief Executive Officer at Suprema, said the recent developments show a shift in how organisations view AI-based access control.

"The record-breaking sales performance and global award recognition of BioStation 3 demonstrate how AI-powered facial authentication technology is rapidly establishing its presence in the global market. It is particularly meaningful that major international clients with stringent security requirements have recognized the accuracy and reliability of BioStation 3 and adopted it in real-world projects. Suprema will continue to address emerging challenges in the security industry and lead global standards through continuous innovation that enhances both security and convenience."